COVID-19药物:新常态和SARS-CoV-2组粒变异等突变下生存的必要策略

Q3 Biochemistry, Genetics and Molecular Biology
Dinh chu, N. Bui, Yen Thi, Suong Ngoc
{"title":"COVID-19药物:新常态和SARS-CoV-2组粒变异等突变下生存的必要策略","authors":"Dinh chu, N. Bui, Yen Thi, Suong Ngoc","doi":"10.5455/jabet.2022.d111","DOIUrl":null,"url":null,"abstract":"The COVID-19 pandemic has spread rapidly and caused significant damage to global public health as well as the economy. While the race of vaccine developmentICLE witnessed a spectacular breakthrough with the introduction of highly effective vaccines such as BNT162b2, mRNA-1273, or AZD1222, no specific drug for COVID-19 treatment has been discovered yet. Recently, repurposing drugs classified into three main groups of mechanisms, including antivirus, anti-SARS-CoV-2 antibodies, and immunomodulators, are investigated. As a result, Remdesivir and six other drugs are authorized by the Food and Drug Administration (FDA) to treat patients infected by the SARS-CoV-2. This work aims to highlight that, besides vaccines, COVID-19 drugs should get more attention and be considered as one of the most promising strategies to safely coexist with the SARS-CoV-2 virus in the new normal status and for the mutations of the virus, such as the omicron variant. © 2022, Bangladesh Society for Microbiology, Immunology and Advanced Biotechnology. All rights reserved.","PeriodicalId":36275,"journal":{"name":"Journal of Advanced Biotechnology and Experimental Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 drugs: A necessary strategy for living with COVID-19 in the new normal and the mutations of the SARS-CoV-2 such as omicron variant\",\"authors\":\"Dinh chu, N. Bui, Yen Thi, Suong Ngoc\",\"doi\":\"10.5455/jabet.2022.d111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The COVID-19 pandemic has spread rapidly and caused significant damage to global public health as well as the economy. While the race of vaccine developmentICLE witnessed a spectacular breakthrough with the introduction of highly effective vaccines such as BNT162b2, mRNA-1273, or AZD1222, no specific drug for COVID-19 treatment has been discovered yet. Recently, repurposing drugs classified into three main groups of mechanisms, including antivirus, anti-SARS-CoV-2 antibodies, and immunomodulators, are investigated. As a result, Remdesivir and six other drugs are authorized by the Food and Drug Administration (FDA) to treat patients infected by the SARS-CoV-2. This work aims to highlight that, besides vaccines, COVID-19 drugs should get more attention and be considered as one of the most promising strategies to safely coexist with the SARS-CoV-2 virus in the new normal status and for the mutations of the virus, such as the omicron variant. © 2022, Bangladesh Society for Microbiology, Immunology and Advanced Biotechnology. All rights reserved.\",\"PeriodicalId\":36275,\"journal\":{\"name\":\"Journal of Advanced Biotechnology and Experimental Therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Advanced Biotechnology and Experimental Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5455/jabet.2022.d111\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Advanced Biotechnology and Experimental Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/jabet.2022.d111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

摘要

新冠肺炎疫情迅速蔓延,对全球公共卫生和经济造成重大损害。虽然随着BNT162b2、mRNA-1273、AZD1222等高效疫苗的问世,疫苗开发竞赛取得了惊人的突破,但目前还没有发现针对COVID-19的特异性药物。最近,对药物再利用的研究主要分为三大类机制,包括抗病毒药物、抗sars - cov -2抗体和免疫调节剂。因此,Remdesivir和其他六种药物被美国食品和药物管理局(FDA)批准用于治疗感染SARS-CoV-2的患者。这项工作旨在强调,除了疫苗,COVID-19药物应该得到更多的关注,并被认为是在新常态下与SARS-CoV-2病毒安全共存的最有希望的策略之一,以及病毒的突变,如组粒变异。©2022,孟加拉国微生物学、免疫学和先进生物技术学会。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
COVID-19 drugs: A necessary strategy for living with COVID-19 in the new normal and the mutations of the SARS-CoV-2 such as omicron variant
The COVID-19 pandemic has spread rapidly and caused significant damage to global public health as well as the economy. While the race of vaccine developmentICLE witnessed a spectacular breakthrough with the introduction of highly effective vaccines such as BNT162b2, mRNA-1273, or AZD1222, no specific drug for COVID-19 treatment has been discovered yet. Recently, repurposing drugs classified into three main groups of mechanisms, including antivirus, anti-SARS-CoV-2 antibodies, and immunomodulators, are investigated. As a result, Remdesivir and six other drugs are authorized by the Food and Drug Administration (FDA) to treat patients infected by the SARS-CoV-2. This work aims to highlight that, besides vaccines, COVID-19 drugs should get more attention and be considered as one of the most promising strategies to safely coexist with the SARS-CoV-2 virus in the new normal status and for the mutations of the virus, such as the omicron variant. © 2022, Bangladesh Society for Microbiology, Immunology and Advanced Biotechnology. All rights reserved.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Advanced Biotechnology and Experimental Therapeutics
Journal of Advanced Biotechnology and Experimental Therapeutics Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
1.90
自引率
0.00%
发文量
41
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信